RADX Stock News & Catalysts – Radiopharm Theranostics

FEATURED

UPDATE – International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026

New

NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, November 12, 2026, featuring live webcast

Summary

Nov 9, 2026, 11:56 AM ·Globe Newswire

RECENT

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 12, 2026

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Thursday, November 12, 2026, featuring live webcast

Nov 5, 2026, 8:35 AM ·Globe Newswire

Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases

Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds Radiopharm Theranostics

Nov 4, 2026, 7:00 AM ·Globe Newswire

Radiopharm Theranostics Reports Business Update

Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration Reported positive Phase

Nov 2, 2026, 8:00 AM ·Globe Newswire

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in

Oct 5, 2026, 8:00 AM ·Globe Newswire

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint Meeting with FDA planned on October 1st to align on RAD101Phase 3 pivotal trial protocol Brain

Sep 14, 2026, 8:00 AM ·Globe Newswire

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Positive safety and favourable biodistribution seen in all subjects dosed Imaging data in all evaluable pancreatic cancer patients demonstrated significant tumor uptake Data support the targeting potential

Sep 9, 2026, 7:00 AM ·Globe Newswire

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

SYDNEY, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative

Aug 26, 2026, 7:00 AM ·Globe Newswire

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Advancing RAD202 Phase 1 trial to next dose level of 180mCi in patients with HER2+ advanced solid tumors Previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients demonstrated clinical

Aug 20, 2026, 7:00 AM ·Globe Newswire

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

RAD 101 Phase 2b trial demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial's primary endpoint End-of-Phase 2 meeting with the U.S. FDA scheduled for October 1st , 2026;

Aug 17, 2026, 7:30 AM ·Globe Newswire

Radiopharm Theranostics Reports Business Update

Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpoint Plans to initiate Phase 3 registrational trial

Jul 31, 2026, 7:00 AM ·Globe Newswire

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on

Jul 24, 2026, 7:15 AM ·Globe Newswire

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with

Jul 22, 2026, 7:05 AM ·Globe Newswire

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14)

Jul 22, 2026, 7:00 AM ·Globe Newswire

A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology

Issued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell

May 14, 2026, 9:15 AM ·Globe Newswire

Radiopharm Theranostics Limited RADX · News